{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024532","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.657134+00:00","generated_at":"2026-06-13T08:13:15.809681+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncocyte amends CEO employment agreement; removes 800,000-share performance option grant","bullets":["CEO Joshua Riggs' 800,000-share performance option grant eliminated under amendment dated July 13, 2023.","Company may grant new performance-based options if shareholders approve plan amendment to remove annual individual limit.","Amendment also modifies equity vesting acceleration provisions for time-based awards in certain termination scenarios.","Base salary remains $360,000; target bonus unchanged at 50% of base salary."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024532","json":"https://secwatch.observer/filing/0001493152-23-024532.json","markdown":"https://secwatch.observer/filing/0001493152-23-024532.md","text":"https://secwatch.observer/filing/0001493152-23-024532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/0001493152-23-024532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:13:15.809681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}